今后，原子高科将持续深耕核医学领域，聚焦重大疾病诊疗需求，加大核素药物研发与技术创新投入， 以更优质的产品与服务助力精准医疗发展，为守护人民健康筑起更坚实的屏障。 中国同辐(01763)公布，近日，原子高科股份有限公司(以下简称：原子高科)利用30MeV质子回旋加速 器，首次实现放射性核素锗-68的国产规模化制备，各项指标均符合欧美商业化产品核素要求，这标志 着我国正式具备自主、稳定的锗-68规模化生产能力，为肿瘤患者精准诊断治疗带来福音。目前，世界 上仅有少数国家攻克了锗-68的规模化制备技术。 锗-68是放射性核素镓-68的母体核素，通过衰变生成镓-68。镓-68标记的放射性药物，在核医学领域可 以用于肿瘤的正电子扫描(PET)诊断显像，能够为肿瘤临床诊断治疗提供重要依据。目前，国外已有多 款镓-68药物获批上市用于癌症的诊断，国内亦有13款镓-68药物进入了临床。随着镓-68药物的获批和大 量使用，锗-68在国内外市场的应用前景广阔。 ...

中国同辐(01763)公布，近日，原子高科股份有限公司(以下简称：原子高科)利用30MeV质子回旋加速 器，首次实现放射性核素锗-68的国产规模化制备，各项指标均符合欧美商业化产品核素要求，这标志 着我国正式具备自主、稳定的锗-68规模化生产能力，为肿瘤患者精准诊断治疗带来福音。目前，世界 上仅有少数国家攻克了锗-68的规模化制备技术。 锗-68是放射性核素镓-68的母体核素，通过衰变生成镓-68。镓-68标记的放射性药物，在核医学领域可 以用于肿瘤的正电子扫描(PET)诊断显像，能够为肿瘤临床诊断治疗提供重要依据。目前，国外已有多 款镓-68药物获批上市用于癌症的诊断，国内亦有13款镓-68药物进入了临床。随着镓-68药物的获批和大 量使用，锗-68在国内外市场的应用前景广阔。 今后，原子高科将持续深耕核医学领域，聚焦重大疾病诊疗需求，加大核素药物研发与技术创新投入， 以更优质的产品与服务助力精准医疗发展，为守护人民健康筑起更坚实的屏障。 ...

格隆汇1月29日丨中国同辐(01763.HK)公告，以下公告的中文原稿由中国同辐股份有限公司旗下一间于 全国中小企业股份转让系统上市的附属公司，原子高科股份有限公司(股份代号：430005)于中国境内发 布。 近日，原子高科股份有限公司(以下简称：原子高科)利用30MeV质子回旋加速器，首次实现放射性核素 锗-68的国产规模化制备，各项指标均符合欧美商业化产品核素要求，这标志着我国正式具备自主、稳 定的锗-68规模化生产能力，为肿瘤患者精准诊断治疗带来福音。目前，世界上仅有少数国家攻克了 锗-68的规模化制备技术。 锗-68是放射性核素镓-68的母体核素，通过衰变生成镓-68。镓-68标记的放射性药物，在核医学领域可 以用于肿瘤的正电子扫描(PET)诊断显像，能够为肿瘤临床诊断治疗提供重要依据。目前，国外已有多 款镓-68药物获批上市用于癌症的诊断，国内亦有13款镓-68药物进入了临床。随着镓-68药物的获批和大 量使用，锗-68在国内外市场的应用前景广阔。 今后，原子高科将持续深耕核医学领域，聚焦重大疾病诊疗需求，加大核素药物研发与技术创新投入， 以更优质的产品与服务助力精准医疗发展，为守护人民健康筑起更坚 ...

提升能级，根基在产业。各地两会上，大家不约而同地将构建现代化产业体系作为首要任务，从优 势产业的做强做优到传统制造的潜力挖掘，从新兴产业的抢先布局到特色产业的品牌塑造，各地正以务 实行动筑牢产业发展的"主骨架"。 宜宾抓住产业变革机遇，积极拓展赛道、优化产业生态，打造特色鲜明的现代化产业体系。 过去五年，宜宾工业增加值增长60%，动力电池产业链全国领先，光伏产业规模跃居全省首位。以 光伏产业为例，在2025年行业承压背景下，宜宾光伏产业规模仍达370亿元，同比增长28.5%。"我们要 继续做大做强主导产业，推动现有产能迭代升级，促进关键材料就近配套，构建更具韧性与活力的产业 生态。"宜宾市经济和信息化局相关负责人说。 南充聚焦对传统制造业精益求精的提质升级与延链补链强链。 1月23日，吉利远程新能源商用车集团南充生产基地传来好消息——N72新车型产量已迈过2.2万辆 大关。作为全市规模体量最大的主导产业，南充现有汽车汽配产业规上企业219户，建有国内规模最大 的新能源商用车基地。"今年，我们将加快推进川东北表面处理循环经济产业园项目建设，补齐机械制 造、汽摩配电镀工艺短板，推动产业集群成势。"南充市经济和信息 ...

Core Viewpoint - The article highlights the achievements of researcher Di Cuixia in the field of heavy ion cancer therapy, emphasizing her innovative contributions and dedication to bridging basic research with clinical needs [1][3]. Group 1: Career Development - Di Cuixia transitioned from a background in plant science to tumor radiotherapy, leveraging her expertise in antibody preparation to make significant strides in cancer research [2][3]. - After returning to China in 2010, she joined the Institute of Modern Physics at the Chinese Academy of Sciences, focusing on heavy ion therapy, which was emerging as a leading technology in cancer treatment [2][3]. Group 2: Research Focus - Di Cuixia's research centers on the mechanisms of heavy ion-induced apoptosis in cancer cells, expanding into areas such as radiation sensitizers, overcoming radiotherapy resistance, and personalized radiotherapy [3][4]. - She has successfully secured multiple research grants, including projects from the National Natural Science Foundation and the Ministry of Science and Technology, to support her innovative research [3][4]. Group 3: Clinical Collaboration - Di Cuixia emphasizes the importance of aligning basic research with clinical needs, actively seeking collaborations with hospitals to obtain clinical samples and data [3][4]. - Her efforts have led to strong partnerships with institutions like Lanzhou University First Hospital and the Cancer Hospital of the Chinese Academy of Medical Sciences, facilitating joint research initiatives [4][5]. Group 4: Innovations and Achievements - Di Cuixia has identified the issue of radiotherapy resistance as a critical challenge and is developing radiation sensitizers to enhance the efficacy of conventional radiotherapy [5]. - Preliminary results indicate that these sensitizers can increase tumor cell sensitivity to conventional radiation, potentially addressing a significant barrier in cancer treatment [5]. Group 5: Outreach and Education - In addition to her research, Di Cuixia is committed to science popularization, engaging with schoolchildren to inspire interest in science through hands-on experiments and relatable explanations [6]. - She believes in the vast potential for growth in the field of nuclear medicine in China, where only 20-30% of cancer patients currently receive radiotherapy compared to 70% in the United States [6].

Group 1 - The event held in Taicang City focused on promoting the standardized application of nuclear technology in disease diagnosis, targeted therapy, and efficacy evaluation, aiming for equitable access to quality nuclear medical resources [1] - The "One County, One Department" strategic research platform for nuclear medicine aims to provide comprehensive solutions for the establishment of nuclear medicine departments in grassroots hospitals, supporting the implementation of the "One County, One Department" strategy [1] - The AI innovation platform for nuclear medicine research wards will enhance clinical research quality and efficiency through AI-enabled solutions for clinical trials, radiomics research, and patient follow-up management [1] Group 2 - The establishment of the Kunrun Shengyan (Suzhou) Technology Co., Ltd. in Shaxi is expected to inject strong momentum into the growth of the local biopharmaceutical industry, leveraging its comprehensive core competencies across software, intelligent hardware, algorithms, and data [2] - Kunrun Shengyan is recognized as a major scientific research achievement transformation enterprise under the national "863" program, filling multiple technological gaps in the industry [2]

Core Viewpoint - China Tongru (01763) announced that the project "Establishment of a Multimodal Nuclear Medicine Molecular Imaging System for Pediatric Neuroblastoma," involving Yuanzi Gaoke Co., Ltd., won the first prize at this year's Beijing Medical Science and Technology Awards [1] Group 1: Project Overview - Neuroblastoma is the most common extracranial solid tumor in children, accounting for approximately 8%-10% of pediatric malignant tumors and leading to about 10%-15% of childhood cancer-related deaths [1] - More than half of the patients are classified as high-risk at initial diagnosis, with a poor prognosis and a five-year survival rate of less than 50% [1] - The project focuses on addressing the challenges posed by neuroblastoma, which is referred to as the "king of childhood cancers," and aims to contribute to public health in China [1] Group 2: Technological Achievements - The project has established a complete independent innovation chain from key equipment and core drugs to clinical applications, creating a "multimodal, low-dose, short-duration" precision diagnosis and treatment system for neuroblastoma [1] - Yuanzi Gaoke has developed the positron-emitting radiopharmaceutical sodium fluoride [18F] injection, completed Phase III clinical trials, and successfully registered it, filling a gap in domestic bone imaging radiopharmaceuticals [2] - The company has also led the development of the iodine [123I] sodium solution radiopharmaceutical group standard and collaborated with the Friendship Hospital to provide a basis for standardized production of domestic radiopharmaceuticals [2] Group 3: Strategic Collaboration - Yuanzi Gaoke and the nuclear medicine department of the Friendship Hospital have established a long-term strategic partnership based on the concept of "industry-university-research-medical collaboration" [2] - The collaboration has resulted in significant advancements in radiopharmaceutical supply, research platform construction, and clinical trial promotion [2] - Moving forward, Yuanzi Gaoke will continue to focus on the field of nuclear medicine, increase investment in radiopharmaceutical research and technological innovation, and deepen cooperation with clinical institutions to enhance precision medical development [2]

Core Insights - China Tongfu (01763) announced that the project "Establishment of a Multimodal Nuclear Medicine Molecular Imaging System for Pediatric Neuroblastoma," participated by Atomic High-Tech Co., Ltd., won the first prize at this year's Beijing Medical Science and Technology Awards [1] Group 1: Project Overview - Neuroblastoma is the most common extracranial solid tumor in children, accounting for approximately 8%-10% of pediatric malignant tumors and leading to about 10%-15% of childhood cancer-related deaths [1] - The project focuses on addressing the challenges posed by neuroblastoma, which has a poor prognosis with a 5-year survival rate of less than 50% for high-risk patients [1] - The project aims to establish a complete independent innovation chain for neuroblastoma diagnosis and treatment, utilizing multimodal nuclear medicine molecular imaging technology [1] Group 2: Contributions of Atomic High-Tech - Atomic High-Tech has played a key role in the development of radiopharmaceuticals for neuroblastoma, including the successful registration of sodium fluoride injection, filling a gap in domestic bone imaging radiopharmaceuticals [2] - The company has established a long-term strategic partnership with Friendship Hospital, focusing on collaborative innovation in radiopharmaceutical supply, research platform construction, and clinical trial advancement [2] - Future efforts will include increased investment in radiopharmaceutical research and technology innovation, aiming to enhance precision medicine and safeguard public health [2]

Core Viewpoint - The project "Establishment of a Multimodal Nuclear Medicine Molecular Imaging System for Pediatric Neuroblastoma," completed with the participation of Yuanzi Gaoke Co., Ltd., has won the first prize of the Beijing Medical Science and Technology Award this year [1] Group 1: Project Significance - Neuroblastoma is the most common extracranial solid tumor in children, accounting for approximately 8%-10% of pediatric malignant tumors and leading to about 10%-15% of childhood cancer-related deaths [1] - More than half of the patients are classified as high-risk at initial diagnosis, with a poor prognosis and a 5-year survival rate of less than 50% [1] - The project addresses a significant public health issue affecting children's health in China, focusing on the challenges posed by neuroblastoma, referred to as the "king of childhood cancers" [1] Group 2: Technological Innovation - The project has established a complete independent innovation chain from key equipment and core drugs to clinical applications, after ten years of systematic research [1] - It has developed a multimodal, low-dose, and short-duration nuclear medicine molecular imaging precision diagnosis and treatment system for neuroblastoma, contributing Chinese wisdom and solutions to this global challenge [1]

（股份代號：1763） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 於其他海外監管市場發佈的公告 公司附屬公司榮獲北京醫學科技獎一等獎 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條的規定而發出。 以下公告的中文原稿由中國同輻股份有限公司旗下一間於全國中小企業股份轉讓 系統上市的附屬公司，原子高科股份有限公司（股份代號：430005）於中國境內發 佈。 茲載列原子高科股份有限公司於2025年12月15日於全國中小企業股份轉讓系統網 站(www.neeq.com.cn)刊登的「原子高科股份有限公司關於參與「兒童神經母細胞 瘤多模態核醫學分子影像體系的建立」項目榮獲北京醫學科技獎一等獎的公告」， 僅供參考。 承董事會命 中國同輻股份有限公司 董事長 肖亞飛 中國，北京，2025年12月15日 於 ...